The stock's fall snapped a five-day winning streak.

Hypertension Diagnostics (OTCMKTS:HDII – Get Free Report) and Inovio Pharmaceuticals (NASDAQ:INO – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will ...

This was the stock's fifth consecutive day of gains.

Inovio Pharmaceuticals (NASDAQ:INO – Get Free Report)‘s stock had its “market outperform” rating restated by JMP Securities ...

Shares of Inovio Pharmaceuticals pulled back by 5.3% during Wednesday’s session. The decline may be attributed to profit-taking, as investors assess renewed focus on respiratory illnesses.

JMP Securities analyst Roy Buchanan reiterated a Buy rating on Inovio Pharmaceuticals (INO – Research Report) today and set a price target of ...

H.C. Wainwright lowered the firm’s price target on Inovio (INO) to $3 from $5 and keeps a Neutral rating on the shares after the company ...

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus.

PLYMOUTH MEETING, Pa., Jan. 9, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.